Altamira Therapeutics Ltd. (NASDAQ:CYTO) Sees Significant Increase in Short Interest

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 180,200 shares, a growth of 12.8% from the August 15th total of 159,800 shares. Approximately 8.1% of the company’s shares are short sold. Based on an average daily volume of 438,800 shares, the days-to-cover ratio is currently 0.4 days.

Altamira Therapeutics Trading Down 10.7 %

Shares of NASDAQ CYTO traded down $0.09 during midday trading on Monday, reaching $0.75. 111,783 shares of the stock were exchanged, compared to its average volume of 914,766. Altamira Therapeutics has a 12 month low of $0.73 and a 12 month high of $17.20. The business has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.41.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.